A61K9/34

Method for reducing the incidence and prevalence of human papilloma virus (HPV) and for providing protection against sexually transmitted infections

Methods comprising the insertion of a uterine cervical device into the lower part of the uterine cavity and endocervix for decreasing the incidence of the human papillomavirus in women, mainly types 16 and 18, thus preventing the development of uterine cervical cancer; for modifying the cervical microbiota; for increasing leukocytes and protecting against sexually transmitted infections in women.

Pharmaceutical compositions comprising silica microspheres

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Lower body cavity treatment methods and devices using carbon dioxide and saline
10029054 · 2018-07-24 · ·

A method of treatment for mixed carbon dioxide, carbonic acid, saline and optional active additives for treating lower body cavity ailments includes delivery of dosage of the treatment at specified flow rates, using a) main housing having a hollow central area containing the dosage; b) a dosage dispenser head located at the distal end of the main housing, and having at least one flow channel for movement of the dosage from the main housing through the dosage dispenser head and to external of the dosage dispenser head; c) a dosage release control component located between the main housing and the dosage dispenser head to permit flow of the dosage through the dosage dispenser head in response to increased pressure against the dosage; and d) a pressure-changing moveable component on the main housing.

Topical composition

There is provided a composition for topical application to the penis for the treatment of erectile dysfunction, the composition being free of glyceryl trinitrate (GTN), sildenafil and an acetylcholinesterase inhibitor, and comprising volatile and non-volatile solvents, the volatile solvents comprising a lower alcohol and water and the non-volatile solvents comprising a polyhydric alcohol and a glycol. Preferably, the composition does not contain any pharmaceutically active ingredients for the treatment of erectile dysfunction. Also provided is a method of determining the cooling ability of a test composition, such as the composition described above.

Enteral sustained-release sugar alcohol additive and preparation method and application thereof

An enteral sustained-release sugar alcohol additive including an inner layer structure and an outer layer structure is provided. The inner layer structure contains components of xylitol and agar, and the outer layer structure contains components of carrageenan or gellan gum or xanthan gum or guar gum, vitamin B12, L-arabinose, and fermented Bifidobacterium or fermented Propionibacterium or fermented Lactobacillus. A method of preparing an enteral sustained-release sugar alcohol additive and an application thereof are further provided.